221 related articles for article (PubMed ID: 18329663)
1. Design and optimization of a multiplex anti-influenza peptide immunoassay.
Drummond JE; Shaw EE; Antonello JM; Green T; Page GJ; Motley CO; Wilson KA; Finnefrock AC; Liang X; Casimiro DR
J Immunol Methods; 2008 May; 334(1-2):11-20. PubMed ID: 18329663
[TBL] [Abstract][Full Text] [Related]
2. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.
Bianchi E; Liang X; Ingallinella P; Finotto M; Chastain MA; Fan J; Fu TM; Song HC; Horton MS; Freed DC; Manger W; Wen E; Shi L; Ionescu R; Price C; Wenger M; Emini EA; Cortese R; Ciliberto G; Shiver JW; Pessi A
J Virol; 2005 Jun; 79(12):7380-8. PubMed ID: 15919893
[TBL] [Abstract][Full Text] [Related]
3. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.
Fan J; Liang X; Horton MS; Perry HC; Citron MP; Heidecker GJ; Fu TM; Joyce J; Przysiecki CT; Keller PM; Garsky VM; Ionescu R; Rippeon Y; Shi L; Chastain MA; Condra JH; Davies ME; Liao J; Emini EA; Shiver JW
Vaccine; 2004 Aug; 22(23-24):2993-3003. PubMed ID: 15297047
[TBL] [Abstract][Full Text] [Related]
4. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly.
Lina B; Fletcher MA; Valette M; Saliou P; Aymard M
Biologicals; 2000 Jun; 28(2):95-103. PubMed ID: 10885616
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S
Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults.
Ben-Yehuda A; Joseph A; Zeira E; Even-Chen S; Louria-Hayon I; Babai I; Zakay-Rones Z; Greenbaum E; Barenholz Y; Kedar E
J Med Virol; 2003 Apr; 69(4):560-7. PubMed ID: 12601765
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
Jadhao SJ; Lee CW; Sylte M; Suarez DL
Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
[TBL] [Abstract][Full Text] [Related]
8. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
[TBL] [Abstract][Full Text] [Related]
9. Immunology. Flu antibodies stir new hope for treatment, vaccine.
Leslie M
Science; 2009 Feb; 323(5918):1160. PubMed ID: 19251602
[No Abstract] [Full Text] [Related]
10. The antibody responses to swine influenza virus (SIV) recombinant matrix 1 (rM1), matrix 2 (M2), and hemagglutinin (HA) proteins in pigs with different SIV exposure.
Kitikoon P; Strait EL; Thacker EL
Vet Microbiol; 2008 Jan; 126(1-3):51-62. PubMed ID: 17719187
[TBL] [Abstract][Full Text] [Related]
11. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
[TBL] [Abstract][Full Text] [Related]
12. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
[TBL] [Abstract][Full Text] [Related]
13. A one-size-fits-all flu vaccine?
Kaiser J
Science; 2006 Apr; 312(5772):380-2. PubMed ID: 16627732
[No Abstract] [Full Text] [Related]
14. A multiplexed immunoassay for detection of antibodies against avian influenza virus.
Watson DS; Reddy SM; Brahmakshatriya V; Lupiani B
J Immunol Methods; 2009 Jan; 340(2):123-31. PubMed ID: 19000692
[TBL] [Abstract][Full Text] [Related]
15. Changing perspective on immunization against influenza.
Johansson BE; Brett IC
Vaccine; 2007 Apr; 25(16):3062-5. PubMed ID: 17276554
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the vaccine potential of an influenza A viral hemagglutinin and matrix double insertion DNA plasmid.
Xie H; Liu T; Chen H; Huang X; Ye Z
Vaccine; 2007 Nov; 25(44):7649-55. PubMed ID: 17913307
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses.
Patel A; Tran K; Gray M; Li Y; Ao Z; Yao X; Kobasa D; Kobinger GP
Vaccine; 2009 May; 27(23):3083-9. PubMed ID: 19428922
[TBL] [Abstract][Full Text] [Related]
18. Detection of influenza A and B neutralizing antibodies in vaccinated ferrets and macaques using specific biotin-streptavidin conjugated antibodies.
Sirskyj D; Weltzin R; Golshani A; Anderson D; Bozic J; Diaz-Mitoma F; Azizi A
J Virol Methods; 2010 Feb; 163(2):459-64. PubMed ID: 19913054
[TBL] [Abstract][Full Text] [Related]
19. Haemagglutination-inhibiting antibody to influenza virus.
de Jong JC; Palache AM; Beyer WE; Rimmelzwaan GF; Boon AC; Osterhaus AD
Dev Biol (Basel); 2003; 115():63-73. PubMed ID: 15088777
[TBL] [Abstract][Full Text] [Related]
20. Universal influenza vaccine: the holy grail?
Shaw AR
Expert Rev Vaccines; 2012 Aug; 11(8):923-7. PubMed ID: 23002973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
